JP2012520323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012520323A5 JP2012520323A5 JP2011554236A JP2011554236A JP2012520323A5 JP 2012520323 A5 JP2012520323 A5 JP 2012520323A5 JP 2011554236 A JP2011554236 A JP 2011554236A JP 2011554236 A JP2011554236 A JP 2011554236A JP 2012520323 A5 JP2012520323 A5 JP 2012520323A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- dimer
- taxane
- medicament
- colchicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 27
- 229940123237 Taxane Drugs 0.000 claims 11
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 11
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical class C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 10
- CMEGANPVAXDBPL-INIZCTEOSA-N n-[(7s)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical class C1([C@@H](NC(C)=O)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC CMEGANPVAXDBPL-INIZCTEOSA-N 0.000 claims 10
- 239000002105 nanoparticle Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 102000009027 Albumins Human genes 0.000 claims 4
- 108010088751 Albumins Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- KFSQWRCNSHKOCW-KYJUHHDHSA-N n-[(7s)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]-3-[[(7s)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]carbamoylamino]propanamide Chemical group C1([C@@H](NC(=O)CCNC(=O)N[C@@H]2C3=CC(=O)C(SC)=CC=C3C3=C(OC)C(OC)=C(OC)C=C3CC2)CC2)=CC(=O)C(SC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC KFSQWRCNSHKOCW-KYJUHHDHSA-N 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 206010055031 vascular neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21007409P | 2009-03-13 | 2009-03-13 | |
| US61/210,074 | 2009-03-13 | ||
| PCT/US2010/027159 WO2010105172A1 (en) | 2009-03-13 | 2010-03-12 | Combination therapy with thiocolchicine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012520323A JP2012520323A (ja) | 2012-09-06 |
| JP2012520323A5 true JP2012520323A5 (enExample) | 2013-04-18 |
| JP5725563B2 JP5725563B2 (ja) | 2015-05-27 |
Family
ID=42728818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011554236A Active JP5725563B2 (ja) | 2009-03-13 | 2010-03-12 | チオコルヒチン誘導体との組み合わせ療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20120189701A1 (enExample) |
| EP (1) | EP2405750B1 (enExample) |
| JP (1) | JP5725563B2 (enExample) |
| KR (1) | KR101739598B1 (enExample) |
| CN (1) | CN102427728A (enExample) |
| AU (2) | AU2010224012B2 (enExample) |
| BR (1) | BRPI1008955A2 (enExample) |
| CA (1) | CA2755121A1 (enExample) |
| IL (1) | IL215079A (enExample) |
| MX (1) | MX2011009452A (enExample) |
| NZ (1) | NZ595189A (enExample) |
| WO (1) | WO2010105172A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN103169729A (zh) | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| US7771751B2 (en) | 2005-08-31 | 2010-08-10 | Abraxis Bioscience, Llc | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| US9675578B2 (en) | 2006-12-14 | 2017-06-13 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| EP3417859A1 (en) * | 2007-03-07 | 2018-12-26 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| HRP20192259T1 (hr) | 2009-04-15 | 2020-03-06 | Abraxis Bioscience, Llc | Pripravci nanočestica bez priona i metode njihove proizvodnje |
| CA3051495A1 (en) | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| AU2012249371B2 (en) | 2011-04-28 | 2017-06-08 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| PL2790675T3 (pl) | 2011-12-14 | 2019-12-31 | Abraxis Bioscience, Llc | Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek |
| US10413606B2 (en) | 2012-10-01 | 2019-09-17 | Mayo Foundation For Medical Education And Research | Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| JP6349381B2 (ja) | 2013-03-12 | 2018-06-27 | アブラクシス バイオサイエンス， エルエルシー | 肺がんを処置する方法 |
| JP6309610B2 (ja) | 2013-03-14 | 2018-04-11 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんを処置する方法 |
| EP2924022A1 (en) * | 2014-03-27 | 2015-09-30 | INDENA S.p.A. | Amorphous form of a thiocolchicine derivative |
| KR20170084328A (ko) * | 2014-11-21 | 2017-07-19 | 엘리 디. 에렌프라이스 | 모노클로날 항체의 투여를 위한 병용 요법 |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| SMT202100642T1 (it) | 2015-06-29 | 2022-03-21 | Abraxis Bioscience Llc | Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi |
| KR101748120B1 (ko) * | 2015-07-13 | 2017-06-16 | 서울대학교산학협력단 | 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도 |
| AU2019239953B2 (en) | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| IL292439B2 (en) | 2019-10-28 | 2026-05-01 | Abraxis Bioscience Llc | Pharmaceutical preparations of albumin and rapamycin |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
| US6797691B1 (en) | 1997-07-23 | 2004-09-28 | Northwestern University | Methods and compositions for inhibiting angiogenesis |
| CN1304567C (zh) | 1998-05-29 | 2007-03-14 | 斯克里普斯研究学院 | 使用酪氨酸激酶src调制血管生成的方法和组合物 |
| AU777528B2 (en) | 1999-04-22 | 2004-10-21 | Abraxis Bioscience, Llc | Long term administration of pharmacologically active agents |
| IT1318401B1 (it) * | 2000-03-17 | 2003-08-25 | Indena Spa | Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono. |
| US20040143004A1 (en) | 2002-02-26 | 2004-07-22 | Joseph Fargnoli | Metronomic dosing of taxanes |
| SI1539157T1 (sl) | 2002-09-18 | 2013-11-29 | Trustees Of The University Of Pennsylvania | Rapamicin za uporabo pri inhibiciji ali preprečevanju horoidalne neovaskularizacije |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| WO2005117876A1 (en) | 2004-06-01 | 2005-12-15 | University Of Virginia Patent Foundation | Dual small molecule inhibitors of cancer and angiogenesis |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN103169729A (zh) * | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| CN101291658B (zh) | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| WO2008137148A2 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
| CN101077335A (zh) * | 2007-06-29 | 2007-11-28 | 济南康泉医药科技有限公司 | 一种含酪氨酸激酶抑制剂的抗癌组合物 |
-
2010
- 2010-03-12 BR BRPI1008955-1A patent/BRPI1008955A2/pt not_active Application Discontinuation
- 2010-03-12 AU AU2010224012A patent/AU2010224012B2/en active Active
- 2010-03-12 CN CN2010800190167A patent/CN102427728A/zh active Pending
- 2010-03-12 NZ NZ595189A patent/NZ595189A/xx unknown
- 2010-03-12 WO PCT/US2010/027159 patent/WO2010105172A1/en not_active Ceased
- 2010-03-12 CA CA2755121A patent/CA2755121A1/en not_active Abandoned
- 2010-03-12 KR KR1020117023842A patent/KR101739598B1/ko active Active
- 2010-03-12 US US13/255,893 patent/US20120189701A1/en not_active Abandoned
- 2010-03-12 MX MX2011009452A patent/MX2011009452A/es active IP Right Grant
- 2010-03-12 EP EP10751482.0A patent/EP2405750B1/en active Active
- 2010-03-12 JP JP2011554236A patent/JP5725563B2/ja active Active
-
2011
- 2011-09-11 IL IL215079A patent/IL215079A/en active IP Right Grant
-
2016
- 2016-07-22 US US15/217,763 patent/US20170105951A1/en not_active Abandoned
- 2016-07-27 AU AU2016208343A patent/AU2016208343A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liang et al. | Monotherapy and combination therapy using anti‐angiogenic nanoagents to fight cancer | |
| Boateng et al. | Delivery of nanoparticle-based radiosensitizers for radiotherapy applications | |
| Duan et al. | Advances and prospects in the treatment of pancreatic cancer | |
| Edis et al. | Nanocarriers-mediated drug delivery systems for anticancer agents: an overview and perspectives | |
| Hheidari et al. | Metal-based nanoparticle in cancer treatment: lessons learned and challenges | |
| Shrestha et al. | Nanoparticles‐mediated combination therapies for cancer treatment | |
| Ding et al. | NIR-responsive polypeptide nanocomposite generates NO gas, mild photothermia, and chemotherapy to reverse multidrug-resistant cancer | |
| Wang et al. | Janus gold nanoplatform for synergetic chemoradiotherapy and computed tomography imaging of hepatocellular carcinoma | |
| Lee et al. | A review on current nanomaterials and their drug conjugate for targeted breast cancer treatment | |
| Tang et al. | The use of nanoparticulates to treat breast cancer | |
| Yao et al. | Mesoporous silica nanoparticles capped with graphene quantum dots for potential chemo–photothermal synergistic cancer therapy | |
| JP2013527232A5 (enExample) | ||
| Alsaab et al. | Nanomaterials for antiangiogenic therapies for cancer: a promising tool for personalized medicine | |
| Liu et al. | Gold nanorods/mesoporous silica-based nanocomposite as theranostic agents for targeting near-infrared imaging and photothermal therapy induced with laser | |
| Mahmoudi et al. | Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy | |
| Yong et al. | Tungsten sulfide quantum dots as multifunctional nanotheranostics for in vivo dual-modal image-guided photothermal/radiotherapy synergistic therapy | |
| Habibi et al. | Emerging methods in therapeutics using multifunctional nanoparticles | |
| Moorthi et al. | Curcumin–Piperine/Curcumin–Quercetin/Curcumin–Silibinin dual drug-loaded nanoparticulate combination therapy: A novel approach to target and treat multidrug-resistant cancers | |
| RU2009121568A (ru) | Комбинации и способы введения терапевтических агентов и комбинированная терапия | |
| Bao et al. | Synergistic effect of tangeretin and atorvastatin for colon cancer combination therapy: targeted delivery of these dual drugs using RGD peptide decorated nanocarriers | |
| Yadav et al. | Novel nanomaterials as photo‐activated cancer diagnostics and therapy | |
| Wang et al. | Gold nanoparticle-mediated delivery of paclitaxel and nucleic acids for cancer therapy | |
| JP2013533232A5 (enExample) | ||
| JP2010509331A5 (enExample) | ||
| Gu et al. | Albumin-bioinspired iridium oxide nanoplatform with high photothermal conversion efficiency for synergistic chemo-photothermal of osteosarcoma |